A Phase I Trial Evaluating the Safety and Efficacy of Vorinostat (Zolinza) + RVD (Lenalidomide [Revlimid] + Bortezomib [Velcade] + Dexamethasone) for Patients With Newly Diagnosed Multiple Myeloma

Trial Profile

A Phase I Trial Evaluating the Safety and Efficacy of Vorinostat (Zolinza) + RVD (Lenalidomide [Revlimid] + Bortezomib [Velcade] + Dexamethasone) for Patients With Newly Diagnosed Multiple Myeloma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Feb 2017

At a glance

  • Drugs Bortezomib (Primary) ; Lenalidomide (Primary) ; Vorinostat (Primary) ; Dexamethasone
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Most Recent Events

    • 18 Jan 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Jan 2018.
    • 18 Jan 2017 Planned End Date changed from 1 Jan 2017 to 1 Jan 2018.
    • 15 Jan 2016 Planned End Date changed from 1 Dec 2015 to 1 Jan 2017, as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top